Introduction
============

Spontaneous remission (SR) in advanced-stage cancer is a rare but notable event, as it reveals the potential inherent reversibility of a fatal disease. Ignorance of physicians with regard to this phenomenon can provoke rejection of medical advice by the patient. It may even support the acceptance of quackery when cases of SR are attributed to dubious therapies ([@b1-ol-0-0-7288]). Although poorly understood, SR is a sufficiently documented phenomenon in several types of cancer, most frequently reported in malignant melanoma, neuroblastoma, nephroblastoma and malignant lymphoma ([@b2-ol-0-0-7288]). Everson ([@b3-ol-0-0-7288]) defined it as the 'disappearance of a malignant tumor in the absence of all treatment or in the presence of therapy which is considered inadequate to exert a significant influence on neoplastic disease'. Positive effects of infectious disease on the course of leukemia were reported by Dock ([@b4-ol-0-0-7288]) as early as 1904. Bierman *et al* ([@b5-ol-0-0-7288]) described 11 cases of SR of ALL in detail, and identified recurring patterns. The frequency of SR in ALL may be as high as 4% ([@b6-ol-0-0-7288]), but the overall incidence of ALL is low and such cases are now less frequently observed due to the rapid initiation of highly effective therapies. Herein is described a case of common-ALL followed by sepsis and a transient complete remission of leukemia. The observations are exemplary and indicate a close association of SR in ALL with an ALL disease-variant termed prodromal or preceding-ALL (pre-ALL).

Case
====

The patient, a pregnant (gravida I, 30 weeks of gestation) 31-year-old female, was admitted to the Department of Gynecology at Nuremberg Hospital (Nuremberg, Germany) in April 2014 with severe anemia, progressive fatigue and excessive sweating. Hemoglobin concentration (Hb) was 5.0 g/dl and the differential count indicated lymphocytosis and severe neutropenia. Hb was 13.2 g/dl at the beginning of gestation and 9.7 g/dl one month prior to admission. A total of four units of erythrocyte concentrates were transfused. Within four days the patient\'s leukocytes rose to 30.8/nl, consisting of 91% mainly atypical lymphocytes consistent with leukemic blasts ([Fig. 1](#f1-ol-0-0-7288){ref-type="fig"}). The patient then left hospital against medical advice.

On an ambulatory visit two days later, enlarged cervical lymph nodes were noted and the complete blood count (CBC) indicated progressive leukocytosis ([Fig. 2](#f2-ol-0-0-7288){ref-type="fig"}). Flow cytometry analysis of peripheral blood samples demonstrated mainly CD45 low leukocytes that expressed CD10, CD19, HLA-DR, CD20, cytoplasmic CD79a and terminal deoxynucleotidyl transferase ([Fig. 3](#f3-ol-0-0-7288){ref-type="fig"}). Chromosome analysis depicted a 46,XX karyotype in 7/17, and a 46,XX,del(5)(q13q22) karyotype in 10/17 metaphases. Fluorescent *in situ* hybridization (FISH) analysis demonstrated an ACSL6 deletion in 85/100 interphase chromosomes. BCR-ABL1, MLL rearrangement or CDKN2A-deletions were not detected, and reverse transcription polymerase chain reaction was negative for BCR-ABL fusion products ([Table I](#tI-ol-0-0-7288){ref-type="table"}). Based on the flow cytometry findings, a diagnosis of common-ALL was determined. The patient refused bone marrow examination, as well as leukemia directed therapy or steroids. Over the next 8 days, the leucocyte count spontaneously dropped to 13/nl; the thrombocyte count and Hb also decreased without treatment.

A total of 16 day following initial presentation, the patient was admitted with preterm uterine contractions, rupture of the membranes, fever, pancytopenia and elevated inflammation markers. The patient delivered a preterm, otherwise healthy, infant via cesarean section and antibiotics were administered for suspected neutropenic colitis. Simultaneously with clinical improvement, the patient\'s CBC and LDH began to normalize. Another 2 weeks later, no atypical lymphocytes were detectable on microscopic blood film examination, and flow cytometry demonstrated a decreased amount of CD45 low leukocytes. FISH was negative for ACSL-6 deletion in 100 analyzed interphase chromosomes ([Table I](#tI-ol-0-0-7288){ref-type="table"}). After 2 more weeks, flow cytometry of peripheral blood samples was negative for ALL, lymphadenopathy had resolved and the patient reported feeling well. At 6 weeks following discharge, the CBC was completely normal. However, after another 2 weeks, the patient presented with persistent rhinitis symptoms, swelling of the lips and urticarial rash. Prior to admission, the patient had been treated with penicillin and doxycycline for suspected sinusitis. LDH was elevated to 958 U/l, the leukocyte count had increased to 31/nl with 50% atypical lymphocytes and hyperplasia of the adenoid tissue, associated with lymphoma, were noted.

A diagnosis of ALL relapse was determined, but the patient deferred all treatment except steroids, and emphasized their belief in recovery without chemotherapy. The patient received cefuroxime and a short course of prednisone. After 4 days, steroids had been tapered and the symptoms and lab results were again improving. However, flow cytometry analysis and molecular diagnostics ([Table I](#tI-ol-0-0-7288){ref-type="table"}) verified relapse. One month later, the patient presented with progressive symptoms from ALL, including anemia, thrombocytopenia, high blast count and abdominal pain. The following 6 weeks were characterized by clinical deterioration and infectious complications. During this time, treatment was limited to supportive measures, including antibiotics, transfusion of erythrocyte and thrombocytes concentrates and a short course of steroids, according to the patient\'s own explicit wishes. The patient then initiated treatment at a naturopathic clinic, from where they were urgently transferred because of life threatening sepsis. The patient received antibiotics and antifungal agents, and finally agreed to ALL-specific therapy, according to the German Multicenter Study Group on Adult Acute Lymphoblastic Leukemia (GMALL) study protocol 07/2003 ([@b7-ol-0-0-7288]). Disease manifestations rapidly improved, and induction phase I was completed with good adherence to the protocol standards.

Bone marrow biopsy verified complete molecular remission of ALL following induction therapy phase I. After three months, while undergoing induction therapy phase II and a modified consolidation therapy, the patient again developed life-threatening infectious complications with neutropenia, severe fatigue and marked nausea. Following consolidation phase II with one course of pegylated asparaginase, the patient declined further systemic therapy. A total of 14 months following the final ALL treatment, and 30 months after the initial diagnosis, bone marrow examination confirmed ongoing complete hematological and molecular remission. The full clinical course is summarized in [Fig. 4](#f4-ol-0-0-7288){ref-type="fig"}. Chromosome analysis was supplemented by comparative-genomic-hybridization array analysis and FISH. Quantification is depicted as a rate of any certain characteristic from all evaluated metaphase or interphase chromosomes \[X/Y\]. FISH could not demonstrate a BCR-ABL1 or MLL rearrangement or a CDKN2A-deletion and reverse transcription polymerase chain reaction (PCR) was negative for BCR-ABL fusion products. Molecular screening-PCRs identified suitable molecular markers for the quantitative evaluation of minimal-residual-disease (MRD). The combination of tests for two different monoclonal rearranged genes: i) Immuno-globulin heavy chain (IGH DH2.21-JH3) and ii) γ-chain of the T-cell receptor (TRG Vγ2-JγP1) yields an assay sensitivity of 1×10^−5^ (0,001% of nucleated cells).

Discussion
==========

Case reports of SRs of ALL collected by Hirshberg and O\'Regan ([@b2-ol-0-0-7288]) up to 1993, and the few published thereafter ([@b8-ol-0-0-7288]--[@b12-ol-0-0-7288]), typically describe a pattern of feverish or septic disease followed by quick but transient remission. If steroids are used, remissions are usually not considered spontaneous due to their well-characterized anti-leukemic effect ([@b13-ol-0-0-7288]). The use of antibiotics and blood transfusions is frequently described, but no individual supportive treatment has been identified as causally associated with the development of SR. It is noteworthy that pre-ALL, a disease variant of ALL that occurs in \~2% of all ALL cases ([@b14-ol-0-0-7288]--[@b16-ol-0-0-7288]), resembles a number of features of SR: The majority of patients are female, and present with fever, fatigue and hypoplastic bone marrow or cytopenia. Occasionally, lymphadenopathy, hepatosplenomegaly and relative lymphocytosis are observed. Although mostly diagnosed with aplastic anemia, patients can recover and develop complete, if transient, recovery of normal bone marrow function. In the majority of cases, 1--14 months following remission patients present with early B-lymphoblastic leukemia ([@b17-ol-0-0-7288]--[@b19-ol-0-0-7288]). The present case observations support an earlier report by Boonchalermvichian *et al* ([@b10-ol-0-0-7288]), and suggest that pre-ALL and SR in ALL may actually represent different stages of the same ALL disease variant. Distinctive classification of pre-ALL and SR in ALL can be attributed to variations in the time of presentation and the limited sensitivity of current diagnostic tests ([Fig. 5](#f5-ol-0-0-7288){ref-type="fig"}).

An important limitation of this report is the lack of bone marrow biopsy data prior to the initiation of leukemia-specific treatment and minimal residual disease studies following SR. More sensitive tests would have been helpful to better characterize the disease and the degree of SR. The concept that in cases of pre-ALL an overt malignant condition may exist initially undetected but potentially traceable by molecular tests, is supported by numerous retrospective analyses ([@b16-ol-0-0-7288],[@b19-ol-0-0-7288]--[@b21-ol-0-0-7288]), and by a case report of a patient who received allogenic stem cell transplantation for suspected severe aplastic anemia and later developed ALL originating from hosts cells ([@b22-ol-0-0-7288]). A review of the literature did not reveal any specific patterns of cytogenetic abnormalities in SR or pre-ALL.

The 6 case reports of SR of ALL post-1993 contained 5 chromosome analyses, of which 2 were normal ([@b8-ol-0-0-7288]--[@b12-ol-0-0-7288]). In 64 reported cases of childhood or adult pre-ALL ([@b10-ol-0-0-7288],[@b14-ol-0-0-7288]--[@b20-ol-0-0-7288],[@b23-ol-0-0-7288]--[@b38-ol-0-0-7288]) only 10 chromosome analyses were reported in the aleukemic phase, of which 9 were normal. In the following overt ALL phase, 14 cytogenetic tests were performed, of which 8 were normal. The described cytogenetic abnormalities included complex karyotypes, numeric alterations as well as translocation and derivations in SR and in pre-ALL. A recently published study did not report classical cytogenetic studies but retrospectively analyzed specimens of the aleukemic phase of 8 cases of pre-ALL, and detected ETV6-RUNX1 fusions in bone marrow cells that were also present during overt ALL ([@b21-ol-0-0-7288]). The study suggested that in pre-ALL established (pre-)leukemic clones are temporarily controlled by the immune system until eventually dominant subclones are selected and induce clinical ALL ([@b21-ol-0-0-7288]).

Various mechanisms, including apoptosis, endogenous steroid effects and immunological reactions following infections, have been proposed to explain occurrence of SR ([@b39-ol-0-0-7288]). The assumption that anti-leukemic immune reactions serve a major role in many cases may be primarily derived from the observation that infections and fever often precede remission. Additionally, an accumulation of T-cells was reported in histological specimens from the bone marrow of patients with pre-ALL or SR of ALL ([@b10-ol-0-0-7288],[@b17-ol-0-0-7288]). Cytokines, such as tumor necrosis factor-α or interferon-γ, which are produced during infection, are potent modulators of immune cells and can induce direct and indirect antitumor activity ([@b40-ol-0-0-7288]). Pro-inflammatory cytokines are also capable of suppressing normal hematopoiesis under certain conditions ([@b41-ol-0-0-7288]), providing a possible linkage for aplasia and remission. It is suggested that pro-inflammatory cytokines and immune cell activity during severe infection shift the balance of pro-leukemia towards an anti-leukemia environment, and induce temporary remission of ALL and a suppression of hematopoiesis.

Further elucidation of the processes underlying SR is required, as it may translate into novel treatment strategies for ALL. Studies that investigate the mechanisms of SR are challenging to perform, but one feasible approach is the implementation of register studies and the bio-banking of material to facilitate retrospective analyses. A relevant clinical question is how to handle cases of SR in ALL. An early implementation of cytotoxic therapy during SR in ALL may be favorable, as the remissions are transient. However, there is no direct evidence to support this approach, and the few recent case reports have indicated that the majority of patients with SR of ALL are cured following relapse using established therapies. Thus, the prognosis of patients with pre-ALL appears to be identical to that of classical ALL cases ([@b15-ol-0-0-7288],[@b38-ol-0-0-7288],[@b42-ol-0-0-7288]).

![Initial diagnosis of ALL. Microscopic image of a Giemsa-Wright stained peripheral blood smear at presentation. Magnification, ×100. ALL, acute lymphoblastic leukemia.](ol-15-01-0115-g00){#f1-ol-0-0-7288}

![Course of disease. Changes in leucocyte count (10^9^/l), LDH (U/l) and rate of CD45 low (%MNC) leucocytes in the peripheral blood by flow cytometry. Timeline is presented as the days following presentation. LDH, lactate dehydrogenase; CD, cluster of differentiation; MNC, mononuclear cell.](ol-15-01-0115-g01){#f2-ol-0-0-7288}

![Flow cytometry analysis of peripheral blood at the time of initial ALL diagnosis. ALL, acute lymphoblastic leukemia; CD, cluster of differentiation; PE, phycoerythrin; FITC, fluorescein isothiocyanate; TdT, terminal deoxynucleotidyl transferase.](ol-15-01-0115-g02){#f3-ol-0-0-7288}

![Timeline of clinical events and therapeutic interventions, listed as the days following presentation. CR, complete remission.](ol-15-01-0115-g03){#f4-ol-0-0-7288}

![Model of spontaneous remission in ALL and preceding-ALL kinetics. Small variations in the time of observation or the diagnostic sensitivity could account for the distinctive classification of the same entity as either preceding-ALL or as spontaneous remission of ALL. ALL, acute lymphoblastic leukemia.](ol-15-01-0115-g04){#f5-ol-0-0-7288}

###### 

Cytogenetics and molecular tests performed on peripheral blood and bone marrow samples.

  Days post presentation   Material           Cytogenetic/FISH                                 MRD-level        Comment
  ------------------------ ------------------ ------------------------------------------------ ---------------- -----------------------
  +8 d                     Peripheral blood   46,XX \[7/17\]; 46,XX,del(5)(q13q22) \[10/17\]     3×10^−1^       Initial diagnosis
  +8 d                     Peripheral blood   FISH: ACSL6-deletion \[85/100\]                    3×10^−1^       Initial diagnosis
  +26 d                    Peripheral blood   46,XX \[6/6\]/FISH: ACSL6-deletion \[0/100\]     Not determined   Spontaneous remission
  +91 d                    Peripheral blood   46,XX \[8/10\]; 46,XX,del(5)(q21q31) \[2/10\]      2×10^−2^       Relapse
  +133 d                   Peripheral blood   46,XX \[11/11\]/FISH: ACSL6-Deletion \[0/100\]   Not determined   Progression
  +194 d                   Peripheral blood   Not determined                                     5×10^−4^       Following pre-phase
  +194 d                   Bone marrow        Not determined                                     1×10^−2^       Following pre-phase
  +224 d                   Bone marrow        FISH: ACSL6-deletion \[0/100\]                   \<5×10^−5^       Following induction I
  +452 d                   Bone marrow        Not determined                                   \<5×10^−5^       Start consolidation
  +553 d                   Bone marrow        Not determined                                   \<5×10^−5^       Follow-up
  +924 d                   Bone marrow        Not determined                                   \<5×10^−5^       Follow-up

FISH, fluorescence *in situ* hybridization; MRD, minimal residual disease.
